BiotechTube
Home/Gilead Sciences/Cindy Perettie
CP

Cindy Perettie

Executive Vice President, Kite Pharma

Gilead Sciences

Therapeutic Areas

VirologyOncologyInflammation

Gilead Sciences Pipeline

DrugIndicationPhase
LenacapavirHIV PrEPPhase 3
Selgantolimod (GS-9688)Chronic Hepatitis BPhase 2
BulevirtideChronic Hepatitis D (U.S.)NDA Submitted
Magrolimab + AzacitidineHigher-Risk MDSPhase 3
TrodelvyHR+/HER2- Metastatic Breast CancerPhase 3 / Approved
YescartaEarlier-line LBCLPhase 3
KITE-363B-cell MalignanciesPhase 1/2
GS-1811Solid TumorsPhase 1

Leadership Team at Gilead Sciences

DO
Daniel O’Day
Chairman & Chief Executive Officer
AD
Andrew Dickinson
Chief Financial Officer
MP
Merdad Parsey
Chief Medical Officer
JM
Johanna Mercier
Chief Commercial Officer
LG
Linda Grett
EVP, Pharmaceutical Development & Manufacturing
View full Gilead Sciences profile